{"id":579698,"date":"2021-12-20T17:08:02","date_gmt":"2021-12-20T17:08:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=579698"},"modified":"2021-12-20T17:08:02","modified_gmt":"2021-12-20T17:08:02","slug":"giant-axonal-neuropathy-pipeline-analysis-report-2021-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-therapies-and-treatment-algorithm","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/giant-axonal-neuropathy-pipeline-analysis-report-2021-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-therapies-and-treatment-algorithm_579698.html","title":{"rendered":"Giant Axonal Neuropathy Pipeline Analysis Report 2021 &#8211; Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Therapies, and Treatment Algorithm"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Giant Axonal Neuropathy Pipeline Analysis Report 2021 - Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Therapies, and Treatment Algorithm\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Giant Axonal Neuropathy Pipeline Analysis Report 2021 - Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Therapies, and Treatment Algorithm\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cGiant Axonal Neuropathy Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Giant Axonal Neuropathy Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Giant Axonal Neuropathy Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Giant Axonal Neuropathy Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/c133c0431e4e29f1c90153d8d4c9bc0b.jpg\" alt=\"Giant Axonal Neuropathy Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/giant-axonal-neuropathy-gan-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Giant Axonal Neuropathy Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the treatment of <strong>Giant Axonal Neuropathy<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the <strong>Giant Axonal Neuropathy Treatment<\/strong>.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/giant-axonal-neuropathy-gan-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Giant Axonal Neuropathy key companies<\/strong><\/a> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Giant Axonal Neuropathy Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Giant Axonal Neuropathy market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/giant-axonal-neuropathy-gan-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Giant Axonal Neuropathy Therapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Globally, only a limited number of companies are involved in the development of novel treatment options for Giant Axonal Neuropathy. This might be due to the difficulty in studying GAN, given its inherent heterogeneity and challenges related to the evaluation of ablation, and may be due to its extremely rare nature. However, the dynamics of the GAN market might change in the coming years.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>At present, Taysha Gene Therapies is involved in the development of a pharmaceutical agent for this rare Disorder.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Taysha Gene Therapies is currently evaluating TSHA-120 (Phase I\/II), an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN. The trial is being conducted by the National Institutes of Health (NIH) in close collaboration with a leading patient advocacy group (Hannah&rsquo;s Hope) focused on finding treatments and cures for GAN.<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/giant-axonal-neuropathy-gan-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/giant-axonal-neuropathy-gan-pipeline-insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Giant Axonal Neuropathy&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Giant Axonal Neuropathy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Giant Axonal Neuropathy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Giant Axonal Neuropathy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Giant Axonal Neuropathy Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Giant Axonal Neuropathy Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Giant Axonal Neuropathy Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Giant Axonal Neuropathy Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Giant Axonal Neuropathy Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Giant Axonal Neuropathy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Giant Axonal Neuropathy Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Giant Axonal Neuropathy Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/giant-axonal-neuropathy-gan-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/giant-axonal-neuropathy-gan-pipeline-insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=giant-axonal-neuropathy-pipeline-analysis-report-2021-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-therapies-and-treatment-algorithm\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=giant-axonal-neuropathy-pipeline-analysis-report-2021-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-therapies-and-treatment-algorithm\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cGiant Axonal Neuropathy Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Giant Axonal Neuropathy Market. The Giant Axonal Neuropathy Pipeline report embraces in-depth commercial and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/giant-axonal-neuropathy-pipeline-analysis-report-2021-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-therapies-and-treatment-algorithm_579698.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-579698","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/579698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=579698"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/579698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=579698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=579698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=579698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}